Posts

How CDMO Partnerships Can Accelerate Cell and Gene Therapy Commercialization

Image
Moving a cell or gene therapy from clinical development toward commercial supply requires coordination across process development, manufacturing, analytical testing, quality, regulatory readiness, and supply chain planning. Managing these activities internally can create significant operational and technical demands for biotechnology and pharmaceutical companies. Strategic end to end CDMO services can help developers bring these capabilities together under a coordinated manufacturing strategy. Instead of managing multiple specialized suppliers and internal functions independently, developers can work with a partner that supports several stages of the product lifecycle. For cell and gene therapy programs, this integrated model can improve continuity, simplify technology transfer, and help development teams prepare earlier for commercial manufacturing requirements. Why Commercialization Is Complex for Cell and Gene Therapies Cell and gene therapies have manufacturing requirements that d...
Post a Comment
Read more

How to Build a Release Testing Strategy for Cell Therapy Products

Image
A well-designed Release Testing strategy is essential for determining whether a cell therapy product meets predefined quality requirements before it is released for its intended use. Unlike conventional pharmaceuticals, cell therapies are complex biological products, and their quality can be influenced by starting material variability, manufacturing conditions, processing time, and storage. For biotechnology and pharmaceutical companies, Release Testing should not be treated as the final isolated step in manufacturing. The strongest strategy connects release assays with in-process testing , process knowledge, product characterization, and Good Manufacturing Practice controls. This creates a more complete understanding of product quality and helps reduce the risk of discovering critical issues only after manufacturing is complete. What Is Release Testing for Cell Therapy Products? Release Testing refers to the analytical and quality control activities used to confirm that a manufact...
Post a Comment
Location: Hong Kong
Read more

Release Testing Strategies for Cell and Gene Therapy Products

Image
As cell and gene therapies advance from clinical development to commercial manufacturing, ensuring consistent product quality has become a top priority. Unlike conventional pharmaceuticals, these products are composed of living cells or genetic material that are highly sensitive to manufacturing conditions. A comprehensive Release Testing strategy verifies that every batch meets predefined quality specifications before it reaches patients. When combined with robust in-process testing, release testing forms the foundation of quality assurance for Advanced Therapy Products (ATPs). In 2026, regulatory agencies continue to strengthen expectations for product characterization, analytical validation, and quality control. Manufacturers that implement well-designed release testing programs are better positioned to reduce batch failures, support regulatory submissions, and accelerate commercialization. What Is Release Testing? Release Testing is the final quality assessment performed after man...
Post a Comment
Location: Hong Kong
Read more